Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab Consolidation Post-ASCT in DLBCL
NCT03072771Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2017
- Primary completion
- Apr 2021
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of blinatumomab in diffuse large B-cell lymphoma (DLBCL), sponsored by Washington University School of Medicine. Primary endpoint: Feasibility and tolerability of blinatumomab consolidation. Started Aug 2017; status: completed.
02
Drugs
blinatumomab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03072771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03072771.